Clinical Trial

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

Name: A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL — clinical trial record (NCT06979076)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-05-09.

Trial Details

NCT Number	NCT06979076
Lead Sponsor	MingSight Pharmaceuticals, Inc
Conditions	CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
Enrollment	12 participants
Start Date	2026-07
Primary Completion	2028-09 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-29